An EU comparative analysis of the regulation of clinical trials supervisory bodies in the aftermath of Regulation 536/2014

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

An EU comparative analysis of the regulation of clinical trials supervisory bodies in the aftermath of Regulation 536/2014. / de Miguel Beriain, Iñigo ; Chortara, Theodora ; Minssen, Timo; Feeney, Oliver ; Duardo-Sánchez, Aliuska ; Fernández de Uzquiano, Emma ; Felzmann, Heike ; Lievevrouw, Elisa ; Marelli, Luca ; Mattsson, Titti ; Pulice, Elisabetta ; Raposo, Vera Lúcia ; Robienski, Jürgen ; Penasa, Simone ; Van Hoyweghen, Ine ; Herrmann, Janne Rothmar.

I: European Public Law, Bind 26, Nr. 2, 18.06.2020, s. 307-330.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

de Miguel Beriain, I, Chortara, T, Minssen, T, Feeney, O, Duardo-Sánchez, A, Fernández de Uzquiano, E, Felzmann, H, Lievevrouw, E, Marelli, L, Mattsson, T, Pulice, E, Raposo, VL, Robienski, J, Penasa, S, Van Hoyweghen, I & Herrmann, JR 2020, 'An EU comparative analysis of the regulation of clinical trials supervisory bodies in the aftermath of Regulation 536/2014', European Public Law, bind 26, nr. 2, s. 307-330. <https://kluwerlawonline.com/journalarticle/European+Public+Law/26.2/EURO2020046>

APA

de Miguel Beriain, I., Chortara, T., Minssen, T., Feeney, O., Duardo-Sánchez, A., Fernández de Uzquiano, E., Felzmann, H., Lievevrouw, E., Marelli, L., Mattsson, T., Pulice, E., Raposo, V. L., Robienski, J., Penasa, S., Van Hoyweghen, I., & Herrmann, J. R. (2020). An EU comparative analysis of the regulation of clinical trials supervisory bodies in the aftermath of Regulation 536/2014. European Public Law, 26(2), 307-330. https://kluwerlawonline.com/journalarticle/European+Public+Law/26.2/EURO2020046

Vancouver

de Miguel Beriain I, Chortara T, Minssen T, Feeney O, Duardo-Sánchez A, Fernández de Uzquiano E o.a. An EU comparative analysis of the regulation of clinical trials supervisory bodies in the aftermath of Regulation 536/2014. European Public Law. 2020 jun. 18;26(2):307-330.

Author

de Miguel Beriain, Iñigo ; Chortara, Theodora ; Minssen, Timo ; Feeney, Oliver ; Duardo-Sánchez, Aliuska ; Fernández de Uzquiano, Emma ; Felzmann, Heike ; Lievevrouw, Elisa ; Marelli, Luca ; Mattsson, Titti ; Pulice, Elisabetta ; Raposo, Vera Lúcia ; Robienski, Jürgen ; Penasa, Simone ; Van Hoyweghen, Ine ; Herrmann, Janne Rothmar. / An EU comparative analysis of the regulation of clinical trials supervisory bodies in the aftermath of Regulation 536/2014. I: European Public Law. 2020 ; Bind 26, Nr. 2. s. 307-330.

Bibtex

@article{c09ff605b0d7421784bd77968f64a734,
title = "An EU comparative analysis of the regulation of clinical trials supervisory bodies in the aftermath of Regulation 536/2014",
abstract = "This article delivers a comparative analysis of the implementation of the new clinical trials regulation and the characteristics of the ethics committees located in a wide range of EU Member States. It provides information about key variables, such as the legal framework corresponding to the EU Member State where the committees are located, the organization of the committees, their incentives and disposition to supervise clinical trials, etc. The analysis covers several EU Member States, including Belgium, Denmark, France, Germany, Greece, Ireland, Italy, Poland, Portugal, Spain and Sweden. These have been chosen taking into account several factors, such as their population, geographical location, cultural tradition, as well as the particularities of their current regulation on clinical trials. Together, they form a sample ideally tailored to probe the shape of the regulatory landscape in the EU ahead of the implementation of the new legal framework",
author = "{de Miguel Beriain}, I{\~n}igo and Theodora Chortara and Timo Minssen and Oliver Feeney and Aliuska Duardo-S{\'a}nchez and {Fern{\'a}ndez de Uzquiano}, Emma and Heike Felzmann and Elisa Lievevrouw and Luca Marelli and Titti Mattsson and Elisabetta Pulice and Raposo, {Vera L{\'u}cia} and J{\"u}rgen Robienski and Simone Penasa and {Van Hoyweghen}, Ine and Herrmann, {Janne Rothmar}",
year = "2020",
month = jun,
day = "18",
language = "English",
volume = "26",
pages = "307--330",
journal = "European Public Law",
issn = "1354-3725",
publisher = "Kluwer Law International",
number = "2",

}

RIS

TY - JOUR

T1 - An EU comparative analysis of the regulation of clinical trials supervisory bodies in the aftermath of Regulation 536/2014

AU - de Miguel Beriain, Iñigo

AU - Chortara, Theodora

AU - Minssen, Timo

AU - Feeney, Oliver

AU - Duardo-Sánchez, Aliuska

AU - Fernández de Uzquiano, Emma

AU - Felzmann, Heike

AU - Lievevrouw, Elisa

AU - Marelli, Luca

AU - Mattsson, Titti

AU - Pulice, Elisabetta

AU - Raposo, Vera Lúcia

AU - Robienski, Jürgen

AU - Penasa, Simone

AU - Van Hoyweghen, Ine

AU - Herrmann, Janne Rothmar

PY - 2020/6/18

Y1 - 2020/6/18

N2 - This article delivers a comparative analysis of the implementation of the new clinical trials regulation and the characteristics of the ethics committees located in a wide range of EU Member States. It provides information about key variables, such as the legal framework corresponding to the EU Member State where the committees are located, the organization of the committees, their incentives and disposition to supervise clinical trials, etc. The analysis covers several EU Member States, including Belgium, Denmark, France, Germany, Greece, Ireland, Italy, Poland, Portugal, Spain and Sweden. These have been chosen taking into account several factors, such as their population, geographical location, cultural tradition, as well as the particularities of their current regulation on clinical trials. Together, they form a sample ideally tailored to probe the shape of the regulatory landscape in the EU ahead of the implementation of the new legal framework

AB - This article delivers a comparative analysis of the implementation of the new clinical trials regulation and the characteristics of the ethics committees located in a wide range of EU Member States. It provides information about key variables, such as the legal framework corresponding to the EU Member State where the committees are located, the organization of the committees, their incentives and disposition to supervise clinical trials, etc. The analysis covers several EU Member States, including Belgium, Denmark, France, Germany, Greece, Ireland, Italy, Poland, Portugal, Spain and Sweden. These have been chosen taking into account several factors, such as their population, geographical location, cultural tradition, as well as the particularities of their current regulation on clinical trials. Together, they form a sample ideally tailored to probe the shape of the regulatory landscape in the EU ahead of the implementation of the new legal framework

UR - https://kluwerlawonline.com/journalarticle/European+Public+Law/26.2/EURO2020046

M3 - Journal article

VL - 26

SP - 307

EP - 330

JO - European Public Law

JF - European Public Law

SN - 1354-3725

IS - 2

ER -

ID: 222343551